Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Dose-Ranging Study of Tofacitinib in RA
NCT00603512Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2008
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib in rheumatoid arthritis (RA) (5 arms), sponsored by Pfizer. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Jan 2008; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00603512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00603512.